Seaport Therapeutics, Inc. (SPTX) is a pioneering biopharmaceutical firm dedicated to advancing cutting-edge immune-oncology therapies to meet critical unmet medical needs, particularly in the field of oncology. The company leverages innovative technologies and a robust research pipeline to develop targeted treatment solutions for complex diseases, with a strong focus on cancer. Supported by strategic collaborations and an experienced management team, Seaport Therapeutics is well-positioned to drive scientific advancements that enhance patient outcomes and reshape the landscape of cancer treatment and immunotherapy.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-148.66M |
| Operating Margin | 0.00% |
| Return on Equity | -28.10% |
| Return on Assets | -18.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.42 |
| Price-to-Book | 2.82 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $53.53M |
| Float | $18.43M |
| % Insiders | 35.14% |
| % Institutions | 70.93% |
Volatility is currently contracting
The mean of analysts' price targets for Seaport Therapeutics, Inc (SPTX) points to a 77.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Seaport Therapeutics leverages proprietary Glyph technology to enhance bioavailability and safety for CNS drugs, targeting MDD and GAD markets. SPTX maintains a cash runway into 2029, with $427.3 million at June 30, trading at a forward book value discount versus sector peers. Recent clean driving data for GlyphAllo and strong PK data for GlyphAgo de-risk regulatory and commercial pathways ahead of the pivotal BUOY-1 readout.
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Data from Phase 1 Trial of GlyphAgo at European College of Neuropsychopharmacology Congress.
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Doses First Patient in GlyphAgo Phase 2a Trial in Generalized Anxiety Disorder & Sleep Disturbance.
Seaport Therapeutics, Inc. (SPTX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo in Healthy Volunteers.
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers.
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress.
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™.
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics to participate in two upcoming investor conferences.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SPTX and any ticker you trade — then tracks every position and per-strategy win rate.
